{"Symbol": "ACHV", "AssetType": "Common Stock", "Name": "Achieve Life Sciences Inc", "Description": "Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.", "CIK": "949858", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "22722 29TH DR. SE, BOTHELL, WA, UNITED STATES, 98021", "OfficialSite": "https://www.achievelifesciences.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "223583000", "EBITDA": "-52110000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.636", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-1.35", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.654", "ReturnOnEquityTTM": "-1.611", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-1.35", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "15.38", "AnalystRatingStrongBuy": "2", "AnalystRatingBuy": "5", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "6.64", "EVToRevenue": "-", "EVToEBITDA": "-2.424", "Beta": "1.836", "52WeekHigh": "6.03", "52WeekLow": "1.84", "50DayMovingAverage": "4.752", "200DayMovingAverage": "3.661", "SharesOutstanding": "53234000", "SharesFloat": "47123300", "PercentInsiders": "4.366", "PercentInstitutions": "43.164", "DividendDate": "2020-07-31", "ExDividendDate": "None"}